B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered donor cells take on tough leukemia
Disease control Recruiting nowThis study tests a new treatment called UCART22 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapy. UCART22 uses donor immune cells that are engineered to recognize and attack cancer cells carrying …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated May 01, 2026 14:18 UTC
-
New drug cocktail IoVeX aims to tame relapsed leukemia
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs (inotuzumab ozogamicin, venetoclax, and dexamethasone) is safe for people whose B-cell acute lymphoblastic leukemia has returned. About 28 children and adults will receive the treatment over one or two 28-day cycle…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated May 01, 2026 14:18 UTC
-
Personalized chemo dosing may boost CAR T-Cell success in leukemia
Disease control Recruiting nowThis study tests whether giving a personalized dose of fludarabine (a chemotherapy drug) before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New Dual-Target CAR t therapy offers hope for children with Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It is for children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can shr…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo offers hope for older leukemia patients
Disease control Recruiting nowThis study tests a new way to treat a fast-growing blood cancer called B-cell acute lymphoblastic leukemia in older adults (60+) or younger adults who cannot handle strong chemo. The treatment combines a targeted drug (blinatumomab) given as a shot under the skin with milder chem…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New gene therapy targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not responded to standard treatments. The therapy aims to help the body fight cancer cells by targeting a protein called CD19 found on these…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New CAR-T therapy CLIC-2201 enters human trials for tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified to better find and…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Off-the-shelf cell therapy takes on hard-to-treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment called Azer-cel for adults with certain blood cancers (non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related conditions) that have returned or stopped responding to standard therapy. Azer-cel is a type of immune c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Can immune booster cells revive failing leukemia treatment?
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can help CAR-T cells work longer in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Participants whose CAR-T cells show early exhaustion will receive either CIK cells, m…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC